Investorideas.com breaking new for AI and tech stocks

Tuesday, January 18, 2022

#AI #Stock News: GBTs’ (OTCPK: $GTCH) Wireless Motion Detection Patent Application was Approved for Prioritized Examination; #artificialintelligence

 

 



 

#AI #Stock News: GBTs’ (OTCPK: $GTCH) Wireless Motion Detection Patent Application was Approved for Prioritized Examination; #artificialintelligence

 

The “Track 1”, prioritized examination goal is to provide a final disposition within twelve months of prioritized status being granted

 

Santa Monica, CA, January 18, 2022 -- (Investorideas.com Newswire) GBT Technologies Inc. (OTC PINK: GTCH) ("GBT” or the “Company”), wireless motion detection, nonprovisional patent application, was approved on January 2022 for prioritized examination by the United States Patent and Trademark Office (“USPTO”).

 

Read this in full at https://www.investorideas.com/CO/GOPH/news/2022/01181Wireless-Motion-Detection-Patent.asp

 

The Company expects its first USPTO’s office action within the next few months. Prioritized examination is a procedure for expedited review of a patent application. The USPTO’s goal for prioritized examination is to provide a final disposition within twelve months of this prioritized status being granted. The technology, which has assigned an internal code name “Apollo”, is currently under design with the goal of developing a real time movement and position detection system that is based on radio waves. The system will send radio waves within specific frequencies and analyze the reflected information using AI algorithm with the goal of identifying distinctive patterns to construct real time movements and positions.  The goal of Apollo, which is currently under design, is to detect stationary and moving objects using a wireless computer vision system and in turn construct a 3D imaging through neural network algorithms.  The goal is to operate within indoor/outdoor environments in all weather conditions. The technology is once developed planned to enable accurate 3D imaging of people and object’s motion and position within a covered area. Its range could theoretically be extended to cover large regions using repeaters and antenna arrays. GBT believes that the technology can be an innovative computer vision solution to be used for a wide variety of applications among them are autonomous vehicles, health watching and security systems. As a reminder, the Company filed a non-provisional patent application on September 10, 2021, serial number 17471213.  As the Apollo system is currently under design, the Company will face a number of risks in fully developing the system as an initial prototype and then for ultimate commercialization.  These risks include capital and human resource constraints among other risks.  There is no guarantee that we will successfully develop the Apollo. 

 

"We are excited to receive a prioritized examination status for our Apollo patent application, as we strongly believe that this type of technology can offer an innovative wireless solution within many domains. We believe the use of radio technology can enable efficient scan-and-detect capabilities and ultimately provide the ability to virtually enable a system to “see” through walls and other mediums. We intended to implement this technology within the Apollo project to equip it with high-resolution abilities to measure very small movement changes.  We believe these types of capabilities can be efficiently used theoretically in wide variety of domains, for example, measuring human vitals at home, detecting vital abnormalities or falls. We believe another potential use is use as an efficient driver’s monitoring system, detecting impaired or distracted drivers, providing audible/visual alerts; and in extreme cases, taking over the vehicle to ensure safety. Apollo’s range is planned to be extended using repeaters which we believe could potentially make it an excellent solution performing as “eyes” for autonomous vehicles and added security for law enforcement and military applications. It is our goal to develop the Apollo system to use theoretically deep learning technology to enable rapid analysis of the reflected RF data, identifying living entities and objects, and constructing a computerized imaging in real time. As the system is currently under design, we consider the Apollo patent to be one of our major intellectual property assets and we are interested in expediting its application process so that we can start its commercialization” stated Danny Rittman, the Company’s CTO.

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  There is no guarantee that the Company will be successful in implementing this system.  In order to successfully implement this system – other than getting the patent approved by the USPTO, the Company will need to raise adequate capital to support its efforts; and if successful, obtain and develop an actual specific approval. The Company would also need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product.  There is no guarantee that the Company will be successful in any or all of these critical steps. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 


  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

 

 

 

 

 

 

Friday, January 14, 2022

#AIEye #Podcast 648: #Stocks discussed: (NasdaqGS: $MSFT) (NasdaqCM: $POAI) #ArtficialIntelligence



 

#AIEye #Podcast 648: #Stocks discussed: (NasdaqGS: $MSFT) (NasdaqCM: $POAI) #ArtficialIntelligence

 

Microsoft Forms AI Industry Innovation Coalition with US Companies and Organizations, and Predictive Oncology Reports Results from AI Cancer Drug Program

 

Global #Mobile #AI market to Reach $22.08B by 2026

 

Point Roberts WA, Vancouver BC – January 14, 2022  – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of  The AI Eye-  watching stock news, deal tracker and advancements in artificial intelligence

 

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2022/011422-AI-Eye.mp3

 

Read this in full at https://www.investorideas.com/news/2022/artificial-intelligence/01141MSFT-POAI.asp

 

Hear the Ai Eye on Spotify  

 

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

 

Stocks discussed: (NasdaqGS:MSFT) (NasdaqCM:POAI)

 

Yesterday it was announced that Microsoft (NasdaqGS:MSFT), along with several leading public, private, educational and research organizations across the U.S. healthcare and life sciences industries (the Brookings Institution, Cleveland Clinic, Duke Health, Intermountain Healthcare, and more) had formed the Artificial Intelligence Industry Innovation Coalition (AI3C). The aim of the coalition is to maximize “technology to provide recommendations, tooling and best practices for AI in healthcare.” Patty Obermaier, vice president, US Health and Life Sciences, Microsoft, said:

 

"The goal of the newly created AI3C is to establish a pragmatic coalition with public and private organizations to advance health by identifying and addressing significant societal and industry barriers. I am excited about the launch of AI3C and working with its distinguished board as we continue the momentum toward serving the needs of patients and communities through AI innovation."

 

Predictive Oncology Inc. (NasdaqCM:POAI) has reported the preliminary results of its Discovery 2021 program. The program combines proprietary knowledgebase, the AI Machine Learning Program and the TruTumor platform from its subsidiary, Helomics, to create the drug discovery approach PeDAL (Patient-centric Discovery by Active Learning). J. Melville Engle, CEO, Chairman of Predictive Oncology Inc., explained:

 

“PeDAL leads to a better selection of drugs, matching the different cancer types to the patients associated with those cancers and potential treatments, improving the scientific and clinical success of drug development. This also translates to millions of dollars in reduced development costs for our future partners. PeDAL can now deliver a proven system that efficiently drives drug response experiments and pulls patient-centric data into the discovery process.”

 

Global Mobile AI market to Reach $22.08B by 2026

 

A report published by Research and Markets finds that the global Mobile Artificial Intelligence market will grow from about $7.2 billion USD in 2021 to $22.08 billion by 2026, registering a compound annual growth rate (CAGR) of 25.12 percent in the forecast period. The following excerpt from the report’s description outlines some key influences on the market’s growth:

 

Factors such as growing demands for artificial intelligence (AI) in smartphones, rising need for AI-capable processors, and rising investment in AI technologies fuel the growth of the mobile artificial intelligence (AI) market. Artificial intelligence technology is widely employed in various ground-breaking applications in manufacturing, automotive, and video games. AI technology is now used in the smartphone business, and it extends well beyond applications such as digital assistants. Several smartphone makers are striving to create AI capabilities that meet the expectations of their customers. For the worldwide mobile artificial intelligence (AI) industry, more investment in inexpensive AI processors and R&D dedicated to camera applications is an opportunity.

 

The high cost of artificial processors, on the other hand, is a key stumbling block to the worldwide mobile artificial intelligence (AI) market's development.

 

Sam Mowers, Investorideas.com

 

Read and hear other editions of the AI  Eye

 

For a list of artificial intelligence stocks on Investorideas.com visit here

 

Investors can trade these stocks and other ideas on our site using our  list of top stock trading apps including Robinhood , Acorn, Stash  and others.

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors.  Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast ,  Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and  the AI Eye Podcast.

The Investorideas.com podcasts are also available on Apple Podcasts ,  Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts  and most audio platforms available.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

The AI Eye-  Watching stock news, deal tracker and  advancements in artificial intelligence is an original content brand of Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 






Get more Technology stock investor ideas - news, articles, podcasts and stock directories

 

New #Stocks to Watch at Investor Ideas: (Nasdaq: $BFRI) (Nasdaq: $CGTX) (Nasdaq: $EXAI) (CSE: $PBF.C) (CSE: $STGX.C) (CSE: $MJEM.C)

 New #Stocks to Watch at Investor Ideas: (Nasdaq: $BFRI) (Nasdaq: $CGTX) (Nasdaq: $EXAI) (CSE: $PBF.C) (CSE: $STGX.C) (CSE: $MJEM.C)

 

#Biotech, #Mining, #Plant-Based and #Tech Stocks to Watch

 

 

 



 

 

 

 

 

 

 

 

 

Point Roberts WA, Delta BC, January 14, 2022 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining, Plant-Based and Tech. Today’s stocks have been added to our lists of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2022/main/01141Stocks.asp

 

The newest biotech companies are involved in treatments of dermatological conditions, CNS and cancer among other diseases.

 

The latest mining company is focused on cobalt and ‘green metals’, while the newest plant-based company offers a vegan meat alternative derived from hemp.

 

The newest tech company is a social media company for Generation Z’s.

 

New stocks added to the Biotech Stock Directory:

Biofrontera Inc.                      (Nasdaq: BFRI) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.

 

COGNITION THERAPEUTICS INC (Nasdaq: CGTX) is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.

 

Exscientia Ltd. (Nasdaq: EXAI) is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka

 

IO Biotech, Inc. (Nasdaq: IOBT) is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, in clinical studies and its other pipeline candidates through clinical and preclinical development. IO Biotech is headquartered in Copenhagen, Denmark, and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).

 

LianBio (NasdaqGM:LIAN) is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets.

 

MiNK Therapeutics, Inc. (Nasdaq: INKT) is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

 

Pyxis Oncology, Inc. (Nasdaq PYXS) is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

 

Theseus Pharmaceuticals, Inc. (Nasdaq:THRX) is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

 

Vaxxinity, Inc.  (NasdaqGM:VAXX) is purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health.

 

New stocks added to the Mining Stocks Directory:

StrategX Elements Corp. (CSE:STGX) is an exploration company poised to be a significant contributor in the green energy sector and emerging low carbon economy. The Company is currently focused on discovery of cobalt and associated ‘green’ metals in northern Canada. The Company’s property portfolio includes two new regional plays: Project 939 & EA South situated near the shores of the East Arm of the Great Slave Lake, Northwest Territories, and Project M on the Melville peninsula, Nunavut, also located close to tidewater.

 

New stocks added to the Plant-Based Stocks Directory:

Planet Based Foods Global Inc. (CSE:PBF) is focused on producing natural, low processed and nutritional choices that are better for people and the planet. The Company currently offers a high quality, cost-efficient vegan meat alternative derived from hemp proteins including burgers, breakfast sausages, burger crumbles and sausage crumbles.

 

New stocks added to the Tech Stocks Directory:

Mijem Newcomm Tech Inc. (CSE:MJEM) is a social media and technology company providing innovative solutions to create a vibrant social marketplace for Generation Z communities, such as students, to connect and to efficiently buy, sell and trade goods and services on and off campus.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors.  Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast ,  Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and  the AI Eye Podcast.

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto CornerPlay by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate ChangeExploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411